



*cancers*



an Open Access Journal by MDPI

## The Tumor–Immune Interface for Next-Generation Immunotherapy

Guest Editor:

### **Dr. Ziliang Huang**

Molecular Engineering for  
Cellular Imaging and  
Reprogramming, University of  
Southern California, Los Angeles,  
CA, USA

Deadline for manuscript  
submissions:

**30 September 2024**

### **Message from the Guest Editor**

Next-generation immunotherapies aim to modulate the tumor–immune interface by either enhancing anti-tumor immune responses or inhibiting immunosuppressive mechanisms. Overall, the tumor–immune interface is a complex and dynamic system that plays a crucial role in tumor progression and response to immunotherapy. Developing next-generation immunotherapies that can effectively modulate the tumor–immune interface is an active area of research and holds promise for improving outcomes for cancer patients. This Special Issue of *Cancers* therefore encompasses original research articles and comprehensive reviews on all aspects of the tumor–immune interface for next-generation immunotherapy.



[mdpi.com/si/166044](https://mdpi.com/si/166044)

**Special** Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)